CJC-1295 W-DAC 2mg

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH), studied in vitro to investigate GHRH receptor engagement. This peptide contains 30 amino acids and weighs approximately 3647 g/mol.

It was designed with a drug affinity complex (DAC) that binds to serum albumin, a structural modification studied for its relevance to extended stability profiles in laboratory research settings.

Peptide Design: The DAC Albumin-Binding Mechanism

The distinguishing structural feature of CJC-1295 with DAC is its terminal lysine residue, added beyond the native 29-residue GRF sequence, which is conjugated to a maleimidopropionyl group.

This maleimide chemistry is designed to form a covalent bond via Michael addition with the free thiol of cysteine-34 on serum albumin, the most abundant protein in blood plasma.

Researchers studying peptide-conjugation chemistry have examined this maleimide-cysteine coupling approach as one of several strategies for covalently linking a short peptide to a considerably larger carrier protein, in contrast to peptides like the unconjugated GRF(1-29) analog, which carries no such conjugation site and instead relies solely on internal sequence modifications for its more modest stability gains.

Analytical Verification of the DAC Conjugation Site

Because the maleimidopropionyl group is the functional basis for this peptide's albumin-binding capability, analytical verification for DAC-conjugated research peptides typically goes beyond standard sequence and purity confirmation to include mass-spectrometric confirmation that the maleimide group remains intact and unreacted prior to use.

A hydrolyzed or otherwise degraded maleimide group would compromise the peptide's albumin-binding capacity without necessarily altering its overall mass in a way that basic purity testing alone would catch, making this an important additional consideration when reviewing a certificate of analysis for this specific compound.

Storage and Handling Considerations Specific to the Maleimide Group

The reactive maleimide group that defines this peptide's DAC functionality is sensitive to hydrolysis in aqueous environments, more so than the peptide backbone itself.

For this reason, the lyophilized powder is kept under sub-zero freezer conditions in sealed, moisture-limited packaging, since exposure to ambient humidity can gradually degrade the maleimide group even in the solid state.

Comparative Context: Conjugation Chemistry Approaches Among Research Peptides

Maleimide-based albumin conjugation is one of several protein-conjugation strategies studied in peptide chemistry, alongside approaches such as PEGylation and Fc-fusion, each of which uses a distinct chemical linkage to attach a peptide to a larger carrier molecule.

Researchers comparing these approaches have noted that maleimide-cysteine conjugation, as used in this compound, forms its covalent bond through a chemically distinct mechanism from PEGylation's polymer attachment chemistry or Fc-fusion's genetic fusion to an antibody fragment.

Important Notice

This CJC-1295 with DAC formulation is designed strictly for in vitro laboratory research only and is not intended for human use. Its use is limited to controlled laboratory environments for investigating cellular responses related to GH and IGF-1 pathways, and has not been evaluated for safety or efficacy in humans.

Product Information

CJC-1295 with DAC is provided as a lyophilized powder, intended strictly for in vitro laboratory research.